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Purpose/Objective: This randomized phase III trial compared 
clinical outcome of concurrent chemoradiotherapy (CCRT) 
versus neoadjuvant chemotherapy plus radiotherapy (NeoCT-
RT) in patients with advanced nasopharygeal carcinoma 
(NPC). 
Materials and Methods: A total of 256 NPC patients with 
2002 AJCC stage II-IVB were randomized to CCRT or NeoCT-
RT. Both arms received IMRT with similar dosage and 
fractionation. The regimen of chemotherapy were concurrent 
PF (two cycles of concurrent chemotherapy with cisplatin 20 
mg/m2/day + 5-fluorouracil 400 mg/m2/day, 96-hour 
continuous infusion during the first and 5th week) or 
neoadjuvant P-FL (cisplatin 60 mg/m2 D1 and 5-FU 2500 
mg/m2 + Leucovorin 250 mg/m2 D8, repeated every 2 weeks 
for 5 cycles). Post-radiation adjuvant chemotherapy using 
oral tegafur-uracil was recommended to patients with high-
risk factors for one year in both arms. 
Results: Baseline patient characteristics were comparable in 
both arms. NeoCT-RT has better Complete response rates, 
evaluated 2-3 months after radiotherapy than CCRT (96.1% 
vs. 85.0%, P=0.0047). Acute toxicity during radiotherapy 
period revealed a significant reduction of grade 3/4 
nausea/vomiting, mucositis, dermatitis, and weight loss in 
the NeoCT-RT arm. After a minimal follow-up of 60 months, 
26.8% (34/127) and 23.3% (30/129) patients in CCRT and Neo-
RT groups developed tumor relapse respectively. The overall 
survival (5-year rate, 81.6% vs. 85.3%, P=0.1967) and 
progression-free survival (5-year rate, 74.0% vs. 78.9%, 
P=0.3807) were similar in both arms. 
Conclusions: NeoCT-RT has a higher initial complete 
response rate and less grade 3/4 acute toxicities during 
radiotherapy but has similar survivals compared with CCRT in 
patients with advanced NPC.  
 
PO-0639   
PETCT parameters predicting survival among recurrent 
head and neck cancer undergoing Cyberknife re-irradiation 
T. Basu1, T. Kataria1, S. Goyal1, D. Gupta1, A. Srivastava1, A. 
Abhishek1, S. Bisht1, V. Subhramani2, K. KP2 
1Medanta The Medicity, Radiation oncology, Gurgaon, India  
2Medanta The Medicity, Medical Physics, Gurgaon, India  
 
Purpose/Objective: There are established guidelines for 
baseline diagnosis and post treatment surveillance among 
head and neck cancer (HNC) patients with PETCT parameters 
like standardized uptake value (SUV), metabolic tumor 
volume (MTV) and Total lesion glycolysis (TLG). The same 
remains controversial and experimental among post 
irradiation (RT) recurrence especially with SBRT. We 
analyzed the PETCT parameters correlating response and 
survival among post RT recurrent HNC (rHNC) undergoing 
Cyberknife SBRT. 
Materials and Methods: Thirteen (10 male and 3 female) HNC 
patients with post RT recurrence undergoing Cyberknife SBRT 
were analyzed. Six patients had loco-regional recurrences, 
five had nodal while one each had distant nodal and 2nd 
primary HNC. All patients had post treatment follow up PET 
scan and on suspicion had biopsy/FNAC proved recurrences. 
All patients received Cyberknife SBRT alone with median dose 
per fraction 6 Gy (5-12 Gy) in 5 fractions (3-7 fractions). Pre 
Cyberknife median SUVmax, MTV and TLG were calculated 
using custom-designed software. Post Cyberknife at 10-12 
weeks the similar values were recorded again. At the time of 
analysis the last follow up status, objective response and 
median values of PET parameters were used as cutoffs while 
assessing their prognostic potential through Chi sqaure test, 
Cox regression analyses, ROC analysis and Pearson's 
correlation respectively. 
Results: The median values of PETCT SUVmax, MTV and TLG 
pre and post therapy were 14.5/6.19, 25.5/1.43 and 
155.03/7.42 respectively. The median reduction in SUV, MTV 
and TLG pre and post Cyberknife were 21.1, 69.2 and 72.8% 
respectively. With a median gap of 18 months (3-77 months) 
between 1st and 2nd RT, the median recurrent gross tumor 
volume (GTV) was 32.6 cc (9.2-243 cc). The median follow up 
post reRT was 9 months (4-19 months) and 6/13 patients had 
loco-regionally stable disease. 
Chi square test and likelihood ratios between median pre 
therapy SUVmax, MTV and TLG with post Cyberknife response 
showed median pre therapy MTV to be statistically significant 
(p=0.04). The likelihood ratios for median reduction in 
SUVmax, MTV and TLG and post CK response also revealed 
MTV and TLG to be closer to statistical significance (p=0.06). 
There was positive correlation between median PETCT 
parameters and median GTV volumes though statistically not 
significant, but pre therapy median MTV values were most 
important in predicting response. 
Both univariate and multivariate analysis suggested trend 
towards better survival in groups with lower MTV and TLG 
values pre and post therapy. ROC analysis though was not 
sensitive to detect MTV and TLG parameters with survival. 
Conclusions: PETCT parameters like MTV and TLG other than 
SUVmax has definite role among rHNC undergoing Cyberknife 
SBRT. Future prospective studies with larger population and 
serial measurement of SUV, MTV and TLG might actually 
establish predictive cut-off values for response and survival. 
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Purpose/Objective: 18FDG PET-CT is a useful test not only for 
diagnosis, staging, evaluation of treatment response or follow 
up in head and neck cancer (HNC), but either can provide 
important complementary information for radiotherapy 
planning. The aim of this study is to investigate the potential 
impact of using 18FDG PET-CT on radiotherapy target volume 
delineation for HNC through the experience at our Center. 
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Materials and Methods: Between June 2009 and January 
2014, 100 consecutive patients (pts) (90 men, 10 women; 
mean age 60 years, range: 36-80) with HNC, were included in 
the study. The primary tumor sites were: 18% oral cavity, 20% 
oropharynx, 12% hypopharynx, 11% nasopharynx, 37% larynx, 
2% paranasal sinuses. 5% were stage I, 7% stage II, 14% stage 
III, 61% stage IVa, 7% stage IVb and 6% stage IVc. All patients 
were staged according to the American Joint Committee of 
Cancer 7th edition. We performed a contrast-enhanced CT 
and a contrast-enhanced 18FDG PET-CT which was done in the 
specific radiotherapy patient positioning. Both exams were 
compared to analyze a change in the detection of the 
primary tumor or nodal disease by 18FDG PET-CT and 
therefore a modification in the target volume planning (PTV).  
Results: In 6 pts, distance metastases were detected so that 
the intent of the treatment changed into palliative. 
Synchronous tumors were detected in 8 pts. When we 
analyzed he primary tumor defined by the CT and compared 
to the 18FDG PET-CT, it varied in 27% of cases due to 
differences in extension: 16 % increased; 11 % decreased 
which implies a variation in the delineation of tumor-GTV (T-
GTV). Referring to the nodal detection, it globally varied in 
42% cases: 5% pts were down-staged (pts staged as N2c 
changed to N2a, N2b or N1) and 3% (Nx to N0) were in fact 
false positive. This implies a reduction in the size of the 
nodal GTV (N-GTV). On the other hand, there were 17% pts 
affected by nodal disease detected thanks to the 18FDG PET-
CT but not diagnosed by the basal CT. 3% pts were staged as 
N+ (N1, N2a or N2b) but turned out into N2c. Those findings 
required to enlarge the nodal GTV. 
Conclusions: Target volume delineation is crucial in the 
radiotherapy treatment. The detection of metastases, 
additional nodal disease or larger extension in primary tumor 
has a great impact on patient management. The modification 
of the T-GTV and N-GTV implies a variation in the prescribed 
dose that could be related with the disease outcome and the 
final quality of life. 
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Purpose/Objective: To compare the survival between altered 
fractionated (AF) and conventional fractionated (CF) 
radiotherapy during concurrent chemoradiotherapy (CCRT) 
for nasopharyngeal carcinoma (NPC). 
Materials and Methods: A total of 203 patients with 1988 
AJCC stage III and IV NPC were treated by CCRT and followed 
at least 5 years. Radiotherapy was delivered by either a CF 
(70-74 Gy/35-40 fractions/7-8 weeks) or AF (72-75 Gy/45 
fractions/6 weeks) schedule. Both arms received the same 
concurrent chemotherapy, consisting of 96-hour continuous 
infusion of cisplatin and 5-FU during the first and 5th weeks 
of radiotherapy. Survival analysis was estimated by the 
Kaplan-Meier method and compared by the log-rank test. 
Results: The patient characteristics between CF and AF 
groups showed similar distribution. The 5-year nasopharynx 
failure-free, neck failure-free, and distant metastasis failure-
free survival rates were 88% vs. 86% (P=0.7781), 95% vs. 93% 
(P=0.4176), 76% vs. 73% (P=0.4029) for CF and AF arms. The 
5-year rates of overall survival (64% vs. 62%, P=0.4812) and 
progression-free survival (67% vs. 63%, P=0.3829) also showed 
similar for both groups. 
Conclusions: Conventional and altered fractionated 
radiotherapy got similar survival outcome when CCRT 
strategy was used for NPC 
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Purpose/Objective: Decision of replanning to spare the 
parotid gland (PG) during the course of locally advanced head 
and neck cancer (LAHNC) IMRT may be guided by anatomical 
markers. The objectives of the study were to identify these 
markers and generate nomograms: 
- to estimate the PG dose at the fraction; 
- to predict the PG cumulated dose delivered during the full 
treatment. 
Materials and Methods: Eighteen patients received radical 
IMRT (70Gy) for LAHNC. Weekly CTs were used to delineate 
the anatomical structures, in particular the internal and 
external PG, and to calculate the dose distributions at the 
fraction. Mean PG cumulated doses were then estimated on 
the planning CT from the weekly CTs by using deformable 
image registration. PG overdose was calculated by the 
difference between the fraction dose or cumulated dose and 
the planned dose. Correlations between anatomical markers 
and PG overdose were searched. Prediction models 
considering the population variation were generated with 
those anatomical markers. Nomograms were then generated 
to easily estimate the PG overdose. Calibration plots have 
been generated. 
Results: A total of 61% of the PG had an overdose of 3.2 Gy 
(ranging from 0.3 to 10gy) and 39% of the PGs had an 
underdose of -2.3 Gy (ranging from -0.1 to -7.9gy). At the 
fraction, the following anatomical markers were correlated 
with PG overdose (nomogram below) (p=<0.01 and R²=0.72): 
- decrease of the thickness of the neck 
- decrease of the superficial lobe of the PG 
- increase of the deep lobe of the PG 
For the cumulated dose, the PG overdose could be predicted 
from parameters calculated from the first weekly CT 
